Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

After the release of our interim results this week, we’re pleased to share another interview between N4 Pharma’s CEO, Nigel Theobald, and Directors Talk. Nigel discusses the progress made with Nuvec® research projects in the last half and explains our strategy as we move forward with our work – including embarking on the most comprehensive in vivo study to date. Listen to the interview in full below.

Directors Talk interview: N4 Pharma is “entering a defining period”